Description: MorphoSys AG engages in the development of therapeutic antibodies to cure inflammatory and autoimmune diseases, as well as cancer and infectious diseases. The company operates through two business segments; Partnered Discovery and Proprietary Development.
Home Page: www.morphosys.com
MOR Technical Analysis
Semmelweisstrasse 7
Planegg,
82152
Germany
Phone:
49 89 89927 0
Officers
Name | Title |
---|---|
Dr. Jean-Paul Kress M.D. | Chairman of Management Board, MD & CEO |
Mr. Sung H. Lee | CFO & Member of Management Board |
Dr. Marlies Sproll | Special Adviser to the Chief Exec. Officer |
Mr. Klaus De Wall | Head of Accounting & Tax |
Ms. Lara Smith Weber | Head of Controlling, Corp. Fin. & Corp. Devel. |
Dr. Margit Urban | Head of Discovery Alliances & Technologies |
Dr. Anja Pomrehn | Sr. VP & Head of Investor Relations |
Ms. Charlotte Lohmann | Sr. VP of Legal, Compliance & IP and Gen. Counsel |
Mr. Thomas Biegi | VP & Head of Corp. Communications |
Ms. Maria Castresana | Sr. VP & Global Head of HR |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 322.5806 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 5.409 |
Price-to-Sales TTM: | 2.1842 |
IPO Date: | 1999-03-09 |
Fiscal Year End: | December |
Full Time Employees: | 627 |